Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Parkinson Disease 1Neuroendocrine Tumors 1Neuroblastoma 1Lewy Body Disease 1Congenital Hyperinsulinism 1Brain Neoplasms 1

Interventions

Cyclophosphamide 21Carboplatin 17Etoposide 15Doxorubicin 14Vincristine 13Cisplatin 11Melphalan 10Filgrastim 10Radiotherapy 9Isotretinoin 8Topotecan 7Peripheral Blood Stem Cell Transplantation 6Granulocyte Colony-Stimulating Factor 6dinutuximab 5sargramostim 4etoposide phosphate 4Neoadjuvant Therapy 4Magnetic Resonance Spectroscopy 4Busulfan 4Vindesine 3Thiotepa 3Platinum 3Ifosfamide 3Colony-Stimulating Factors 3Chemotherapy, Adjuvant 3Biopsy 33-Iodobenzylguanidine 31,2-diaminocyclohexaneplatinum II citrate 3liposomal amphotericin B 2fluorodopa F 18 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Neuroblastoma × 4-chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid × Clear all
NCT04706910 2026-02-09

18F-DOPA II - PET Imaging Optimization

University of Alberta

Phase 3 Recruiting
800 enrolled
CNSEndocrineNET

Brain Neoplasms, Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Lewy Body Disease, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡